Terremoto Biosciences is a biotechnology company that has raised $175 million in a Series B financing round to advance its platform and support the development of multiple in-house programs targeting diseases of high unmet medical need.

ReCode Therapeutics is a genetic medicines company that uses precision delivery to develop mRNA and gene correction therapeutics, with a focus on treatments for primary ciliary dyskinesia, cystic fibrosis, and other genetic diseases.

Actio Biosciences is a biotechnology company that uses its proprietary platform for genetics and precision medicine to develop therapeutics for both rare and common diseases, with a focus on TRPV4 mutations for the treatment of Charcot-Marie-Tooth disease type 2C and other serious bone diseases.